(TOI) Oncology Institute - Ratings and Ratios

The Oncology Institute, Inc. (NASDAQ:TOI) is a specialized oncology company providing comprehensive cancer care services across the United States. The company operates through three distinct business segments: Dispensary, Patient Services, and Clinical Trials & Other. Its service portfolio includes physician consultations, in-house infusion and dispensary services, clinical trial management, radiation therapy, outpatient blood transfusions, and patient support programs such as educational seminars, support groups, and counseling. Additionally, the company offers palliative care, stem cell transplant services, and clinical trial management for pharmaceutical and medical device companies. The Oncology Institute primarily serves adult and senior cancer patients, focusing on community-based and academic care settings. It has a strategic partnership with Healthly Forge to expand its cancer care services in Southern California. Founded in 2007, the company is headquartered in Cerritos, California.

TOI operates in the healthcare sector, specifically within the Health Care Equipment industry. Its ticker symbol is TOI, listed on the NASDAQ exchange as a common stock. The companys market capitalization stands at $64.38 million USD, with a price-to-book ratio of 4.39, indicating a premium valuation relative to its book value. The average trading volume over 20 days is 731,761 shares, with a last price of $0.66. The stocks short-term moving averages (SMA 20: $0.87, SMA 50: $0.65) suggest a recent downtrend, while the SMA 200 ($0.44) reflects longer-term bearish momentum. The average true range (ATR) of $0.13 highlights moderate volatility.

Three-Month Forecast - Technical Outlook: The stock is likely to face resistance at $0.87 (SMA 20) and $0.65 (SMA 50), with support near $0.44 (SMA 200). The ATR of $0.13 suggests price fluctuations may remain constrained within this range. - Fundamental Analysis: With a market cap of $64.38 million and a P/B ratio of 4.39, TOI is positioned as a small-cap company with a premium valuation. The lack of forward P/E suggests limited visibility into earnings growth. - Three-Month Forecast: Based on technical and fundamental data, TOI is expected to trade sideways to slightly downward, with potential price targets of $0.56 (SMA 50) and $0.44 (SMA 200). Upside could be limited by resistance at $0.65 and $0.87.